SPC401
inebilizumab
Status:
VeittApplication date:
15.9.2022Application published:
15.10.2022Grant published:
15.4.2024
Max expiry date:
6.9.2032Medicine name:
UpliznaMedicine for children:
No
Timeline
Today
15.9.2022Application
15.10.2022Publication
15.4.2024Registration
6.9.2032Expires
Marketing license
IS authorization number:
EU/1/21/1602/001Date:
13.5.2022
Foreign authorization number:
EU/1/21/1602Date:
25.4.2022
Owner
Name:
Viela Bio, Inc.Address:
1 Horizon Way, Deerfield, Illinois 60015 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2066349